Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)

BACKGROUND: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits androgen biosynthesis. The Cancer of the Ovary Ab...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Ther Adv Med Oncol
Main Authors: Banerjee, Susana, Tovey, Holly, Bowen, Rebecca, Folkerd, Elizabeth, Kilburn, Lucy, McLachlan, Jennifer, Hall, Marcia, Tunariu, Nina, Attygalle, Ayoma, Lima, Joao Paulo Da Silveira Nogueira, Perry, Sophie, Chatfield, Peter, Hills, Margaret, Kaye, Stan, Attard, Gert, Dowsett, Mitch, Bliss, Judith M.
Format: Artigo
Sprog:Inglês
Udgivet: SAGE Publications 2020
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013695/
https://ncbi.nlm.nih.gov/pubmed/33854564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920975352
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker